Replies to post #97921 on Biotech Values

[mcbio]

Re: BMY/PFE Apixaban program

Among the nine* Big Pharma mentioned in the Barron’s article posted by turtle, BMY probably has the most upside from the anticoagulant market by dint of the Apixaban program, which is a joint development with PFE.

Does BMY have more upside than PFE due to BMY having a greater participation than PFE in the economics of the Apixaban program or is it because Apixaban revenue will have more of an impact on BMY's bottom-line compared to PFE?